share_log

iBio Inc | 8-K: Current report

iBio Inc | 8-K: Current report

iBio Inc | 8-K:重大事件
美股SEC公告 ·  2024/07/10 04:06

牛牛AI助理已提取核心訊息

On July 2, 2024, iBio's Board approved new forms of award agreements for stock options and restricted stock units under its 2023 Plan. The agreements cover grants to directors, executives, employees, and consultants, with specific provisions for exercise pricing and vesting conditions. Award treatment varies based on termination circumstances, with immediate vesting for death/disability cases and forfeiture for cause terminations.The agreements include special provisions for Sale Events, where non-employee directors receive immediate vesting upon such events. Employees get immediate vesting if terminated without cause or resign with good reason within 12 months after a Sale Event, while officers have similar protections extending one month prior to the Sale Event.Concurrently, the company adopted an updated Code of Business Conduct and Ethics applying to all directors, officers, and employees. The revised code features modernized language and structure, enhanced risk mitigation measures, and better alignment with current operations and work environment.
On July 2, 2024, iBio's Board approved new forms of award agreements for stock options and restricted stock units under its 2023 Plan. The agreements cover grants to directors, executives, employees, and consultants, with specific provisions for exercise pricing and vesting conditions. Award treatment varies based on termination circumstances, with immediate vesting for death/disability cases and forfeiture for cause terminations.The agreements include special provisions for Sale Events, where non-employee directors receive immediate vesting upon such events. Employees get immediate vesting if terminated without cause or resign with good reason within 12 months after a Sale Event, while officers have similar protections extending one month prior to the Sale Event.Concurrently, the company adopted an updated Code of Business Conduct and Ethics applying to all directors, officers, and employees. The revised code features modernized language and structure, enhanced risk mitigation measures, and better alignment with current operations and work environment.
在2024年7月2日,iBio的董事會批准了2023計劃下股票期權和限制性股票單位的新獎項協議。這些協議涵蓋了對董事、執行官、員工和顧問的授予,並對行權價格和歸屬條件進行了具體規定。獎勵處理因終止情況而異,對於死亡/殘疾的情況立即歸屬,而因故終止則會被沒收。這些協議包括針對銷售事件的特別條款,其中非員工董事在此類事件發生時立即歸屬。員工如果在銷售事件後12個月內因無故被終止或因合理理由辭職,則可立即歸屬,而高管在銷售事件前一個月內有類似的保護。同時,公司採用了更新的業務行爲和倫理規範,適用於所有董事、官員和員工。修訂後的規範具有現代化的語言和結構,增強了風險緩解措施,並與當前的運營和工作環境更好地對齊。
在2024年7月2日,iBio的董事會批准了2023計劃下股票期權和限制性股票單位的新獎項協議。這些協議涵蓋了對董事、執行官、員工和顧問的授予,並對行權價格和歸屬條件進行了具體規定。獎勵處理因終止情況而異,對於死亡/殘疾的情況立即歸屬,而因故終止則會被沒收。這些協議包括針對銷售事件的特別條款,其中非員工董事在此類事件發生時立即歸屬。員工如果在銷售事件後12個月內因無故被終止或因合理理由辭職,則可立即歸屬,而高管在銷售事件前一個月內有類似的保護。同時,公司採用了更新的業務行爲和倫理規範,適用於所有董事、官員和員工。修訂後的規範具有現代化的語言和結構,增強了風險緩解措施,並與當前的運營和工作環境更好地對齊。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。